The Chemours Company (NYSE:CC) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. boosted its position in shares of The Chemours Company (NYSE:CC) by 2.7% in the third quarter, Holdings Channel.com reports. The firm owned 1,229,052 shares of the specialty chemicals company’s stock after acquiring an additional 32,590 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Chemours were worth $24,974,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in CC. Marshall Wace LLP grew its holdings in Chemours by 23.8% during the 2nd quarter. Marshall Wace LLP now owns 7,009,868 shares of the specialty chemicals company’s stock worth $158,213,000 after acquiring an additional 1,347,710 shares in the last quarter. Khrom Capital Management LLC boosted its stake in Chemours by 54.6% during the 2nd quarter. Khrom Capital Management LLC now owns 3,456,626 shares of the specialty chemicals company’s stock valued at $78,016,000 after purchasing an additional 1,220,967 shares during the period. Forest Avenue Capital Management LP boosted its stake in Chemours by 236.9% during the 2nd quarter. Forest Avenue Capital Management LP now owns 845,728 shares of the specialty chemicals company’s stock valued at $19,088,000 after purchasing an additional 594,660 shares during the period. American Century Companies Inc. boosted its stake in Chemours by 26.7% during the 2nd quarter. American Century Companies Inc. now owns 1,811,957 shares of the specialty chemicals company’s stock valued at $40,896,000 after purchasing an additional 382,100 shares during the period. Finally, Private Management Group Inc. lifted its stake in shares of Chemours by 72.0% in the 3rd quarter. Private Management Group Inc. now owns 785,809 shares of the specialty chemicals company’s stock worth $15,968,000 after acquiring an additional 329,037 shares during the period. 76.26% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Morgan Stanley reduced their price target on shares of Chemours from $30.00 to $25.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 5th. The Goldman Sachs Group cut their price target on shares of Chemours from $29.00 to $23.00 and set a “neutral” rating on the stock in a report on Tuesday, September 3rd. Barclays boosted their price target on shares of Chemours from $21.00 to $23.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. Royal Bank of Canada dropped their price objective on shares of Chemours from $28.00 to $25.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Finally, BMO Capital Markets upped their price objective on shares of Chemours from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, October 7th. Five research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $24.88.

Chemours Price Performance

NYSE CC opened at $21.10 on Friday. The company has a current ratio of 1.73, a quick ratio of 0.92 and a debt-to-equity ratio of 6.05. The company has a fifty day simple moving average of $19.87 and a 200 day simple moving average of $21.14. The company has a market cap of $3.15 billion, a P/E ratio of 42.20 and a beta of 1.80. The Chemours Company has a 1 year low of $15.10 and a 1 year high of $32.70.

Chemours (NYSE:CC) last released its earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.32 by $0.08. The firm had revenue of $1.50 billion during the quarter, compared to analysts’ expectations of $1.44 billion. Chemours had a net margin of 1.34% and a return on equity of 29.48%. The business’s quarterly revenue was up .9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.64 EPS. On average, sell-side analysts predict that The Chemours Company will post 1.35 EPS for the current year.

Chemours Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 16th. Stockholders of record on Friday, November 15th will be paid a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a dividend yield of 4.74%. The ex-dividend date is Friday, November 15th. Chemours’s dividend payout ratio is 200.00%.

Insider Activity

In related news, SVP Alvenia Scarborough sold 7,500 shares of the stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $20.64, for a total transaction of $154,800.00. Following the completion of the sale, the senior vice president now owns 16,645 shares in the company, valued at $343,552.80. This trade represents a 31.06 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.47% of the company’s stock.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.